In May 2021, Paul Campanelli was appointed as a senior advisor to the firm.
Paul is the former Chairman, President, Chief Executive Officer and Director of Endo International with over 30 years of experience. Paul transformed the organization into an industry-leading generics business and built a strong leadership team with a vision of becoming a highly focused generics and specialty branded pharmaceutical company. Endo delivers quality medicines to patients in need through excellence in development, manufacturing, and commercialization in multiple business segments including U.S. Branded Pharmaceuticals, U.S. Branded Sterile Injectables, U.S. Generic Pharmaceuticals, and International Pharmaceuticals.
Paul’s leadership drove the company to significantly increased total revenue. During his tenure, Par and Endo acquired Michigan-based JHP Pharmaceuticals, established a business office in London to serve as Par’s entry point into the European generics market, and completed its acquisition of an active pharmaceutical ingredients (API) facility located in Chennai, India. Paul also shaped the company’s strategic focus on organic growth through investments in hard-to-produce generic assets and technologies, a highly specialized branded business, and a concentration on differentiated and intelligent product selection.
Earlier in his tenure, Paul served as Chief Operating Officer and President of Par Pharmaceutical, Inc., the company’s generics division, from 2011 to 2012. Mr. Campanelli also held roles of increasing responsibility, including Senior Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by Par’s board of directors. He also served on the board of directors of Sky Growth Holdings Corporation.
Paul currently serves on the board of directors for PAI (Pharmaceutical Associates Inc.), Slayback Pharma, and Convey Health Solutions. Paul previously served on the board of Sky Growth Holdings, a TPG company.